ARTICLE | Clinical News

Liposomal Grb-2: Preliminary Phase I data

February 20, 2012 8:00 AM UTC

Preliminary data from 3 evaluable patients in the second cohort of a dose-escalation Phase I trial showed that twice-weekly 10 mg/m 2 IV BP-100-1.01 for 4 weeks was well tolerated with no treatment-related serious adverse events reported. Three patients in the cohort failed to complete a full 28-day cycle due to disease progression. The company plans to enroll 3 additional cohorts requiring 3 evaluable patients each. Patients will receive 5, 10, 20, 40 or 50 mg/m 2 BP-100-1.01. ...